Monday, December 23, 2024 | 02:31 AM ISTEN Hindi

Home / Markets / News / Nifty Pharma index rises 2% as Sun Pharma, Lupin receive USFDA approval

Nifty Pharma index rises 2% as Sun Pharma, Lupin receive USFDA approval

Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the NSE after the drug maker announced USFDA approval of XELPROS to treat open-angle Glaucoma or Ocular Hypertension.

Premium

The revenue from operations declined to ~69.7 bn for the fourth quarter against ~71.3 bn during the same period last year

SI Reporter New Delhi

Last Updated : Sep 14 2018 | 10:37 AM IST

Shares of pharmaceutical companies were in focus with the Nifty Pharma index rising over 2 per cent to 10,623.60 levels in the intra-day deals after Sun Pharmaceutical Industries (Sun Pharma) and Lupin USFDA approval for their respective medicines.

Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the National Stock Exchange (NSE) after the drug maker announced USFDA approval of XELPROS to treat open-angle Glaucoma or Ocular Hypertension. This approval is from Sun Pharma’s Halol facility.

"XELPROS is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK), a preservative

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in